Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD

Obesity

Volumn 18, Issue 10, 2010, Pages 1969-1974

  Jiang, Chao Qiang ^a   Lam, Tai Hing ^b   Liu, Bin ^a   Lin, Jie Ming ^a   Yue, Xiao Jun ^a   Jin, Ya Li ^a   Cheung, Bernard M Y ^c   Thomas, G Neil ^c  

^a Guangzhou No 12 Hospital   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TRIACYLGLYCEROL;

AGED; ALLELE; ARTICLE; BLOOD; FEMALE; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; POPULATION GENETICS; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; GENETICS, POPULATION; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, INTERLEUKIN-6; RISK FACTORS; TRIGLYCERIDES;

EID: 77957105980     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.31     Document Type: Article

References (42)

1. Thomas GN, Schooling CM, McGhee SM, et al.; Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol (Oxf) 2007;66:666-671.
2. Eberly LE, Prineas R, Cohen JD, et al.; Multiple Risk Factor Intervention Trial Research Group. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006;29:123-130.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
4. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005;54 Suppl 2:S114-S124.
5. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-214.
6. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
7. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.
8. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008;88:1379-1406.
9. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-320.
10. Wong LY, Leung RY, Ong KL, Cheung BM. Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene -572C>G polymorphism in subjects with and without hypertension. J Hum Hypertens 2007;21: 875-882.
11. Lieb W, Pavlik R, Erdmann J, et al. No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004;97:205-212.
12. Testa R, Olivieri F, Bonfigli AR, et al. Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2006;71:299-305.
13. Potaczek DP, Undas A, Nowakowski T, Szczeklik A. Association between inflammatory markers and the interleukin-6 -174 G/C polymorphism is abolished in peripheral arterial occlusive disease. Int Angiol 2007;26: 318-323.
14. Libra M, Signorelli SS, Bevelacqua Y, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006;59:211-215.
15. Jang Y, Kim OY, Hyun YJ, et al. Interleukin-6-572C>G polymorphismassociation with inflammatory variables in Korean men with coronary artery disease. Transl Res 2008;151:154-161.
16. Huth C, Illig T, Herder C, et al. Joint analysis of individual participants data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med 2009;41:128-138.
17. Reich D, Patterson N, Ramesh V, et al.; Health, Aging and Body Composition (Health ABC) Study. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007;80:716-726.
18. Rafiq S, Frayling TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 2007;8:552-559.
19. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. Women. Diabetes 2007;56:3075-3081.
20. Herbert A, Liu C, Karamohamed S, et al. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institutes Framingham Heart Study. Diabetologia 2005;48:1492-1495.
21. Esteve E, Villuendas G, Mallolas J, et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol (Oxf) 2006;65:88-91.
22. Hamid YH, Rose CS, Urhammer SA, et al. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005;48:251-260.
23. Hamid YH, Urhammer SA, Jensen DP, et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 2004;53:3342-3345.
24. Huth C, Heid IM, Vollmert C, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants data from 21 studies. Diabetes 2006;55:2915-2921.
25. Jiang CQ, Lam TH, Lin JM et al. An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. J Hum Hypertens 2010;24:139150.
26. Wang H, Zhang Z, Chu W, et al. Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab 2005;90:1123-1129.
27. Wolford JK, Colligan PB, Gruber JD, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab 2003;80:338-343.
28. Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:27352752.
29. World Health Organization Western Pacific Region. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications, Australia (2000). Accessed 2 Nov 2005.
30. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997;16:2529-2542.
31. Qi L, van Dam RM, Meigs JB, et al. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006;15: 1914-1920.
32. Möhlig M, Boeing H, Spranger J, et al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 2004;89:1885-1890.
33. Kubaszek A, Pihlajamäki J, Komarovski V, et al.; Finnish Diabetes Prevention Study. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003;52:1872-1876.
34. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millán JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003;11: 987-996.
35. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005;48:1038-1050.
36. Hardardóttir I, Grünfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994;5:207-215.
37. Thomas GN, Tomlinson B, Hong AW, Hui SS. Age-related anthropometric remodelling resulting in increased and redistributed adiposity is associated with increases in the prevalence of cardiovascular risk factors in Chinese subjects. Diabetes Metab Res Rev 2006;22:72-78.
38. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-4200.
39. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850.
40. Dovio A, Masera RG, Sartori ML, Racca S, Angeli A. Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int 2001;69:293-298.
41. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10 Suppl 2:81-90; discussion 91.
42. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46: 3143-3150.